EFFICACY AND SAFETY OF BARICITINIB IN JAPANESE RHEUMATOID ARTHRITIS PATIENTS AT 12 WEEKS

被引：0
|
作者：
Tanaka, Y. [1 ]
Emoto, K. [2 ]
Tsujimoto, M. [2 ]
Schlichting, D. [3 ]
Macias, W. [3 ]
机构：
[1] Univ Occupat & Environm Hlth, Kitakyushu, Fukuoka 807, Japan
[2] Eli Lilly Japan KK, Kobe, Hyogo, Japan
[3] Eli Lilly & Co, Indianapolis, IN 46285 USA
来源：
ANNALS OF THE RHEUMATIC DISEASES | 2014年 / 73卷
关键词：
D O I：
10.1136/annrheumdis-2014-eular.1366
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
THU0149
引用
收藏
页码：231 / 231
页数：1
相关论文
共 50 条
  • [31] Response to Baricitinib at 4 Weeks Predicts Response at 12 and 24 Weeks in Patients with Rheumatoid Arthritis: Results from Two Phase 3 Studies
    Kremer, Joel
    Dougados, Maxime
    Genovese, Mark C.
    Emery, Paul
    Yang, Lili
    de Bono, Stephanie
    Holzkaemper, Thorsten
    Iikuni, Noriko
    Schlichting, Douglas E.
    Smolen, Josef S.
    ARTHRITIS & RHEUMATOLOGY, 2015, 67
  • [32] Efficacy and Safety of Extending Tocilizumab Infusion Intervals from 4 Weeks to 6 Weeks in Patients with Rheumatoid Arthritis
    Uda, Hiroshi
    Saiki, Osamu
    ARTHRITIS & RHEUMATOLOGY, 2017, 69
  • [33] Baricitinib in Patients with Refractory Rheumatoid Arthritis
    Genovese, Mark C.
    Kremer, Joel
    Zamani, Omid
    Ludivico, Charles
    Krogulec, Marek
    Xie, Li
    Beattie, Scott D.
    Koch, Alisa E.
    Cardillo, Tracy E.
    Rooney, Terence P.
    Macias, William L.
    de Bono, Stephanie
    Schlichting, Douglas E.
    Smolen, Josef S.
    NEW ENGLAND JOURNAL OF MEDICINE, 2016, 374 (13): : 1243 - 1252
  • [34] Baricitinib in Patients with Refractory Rheumatoid Arthritis
    Lunzer, R.
    JOURNAL FUR MINERALSTOFFWECHSEL & MUSKULOSKELETTALE ERKRANKUNGEN, 2016, 23 (02): : 60 - 61
  • [35] Janus Kinase Inhibitors in Rheumatoid Arthritis: An Update on the Efficacy and Safety of Tofacitinib, Baricitinib and Upadacitinib
    Harrington, Robert
    Harkins, Patricia
    Conway, Richard
    JOURNAL OF CLINICAL MEDICINE, 2023, 12 (20)
  • [36] Efficacy and Safety of Baricitinib in Japanese Patients with Active Rheumatoid Arthritis Receiving Background Methotrexate Therapy: A 12-Week, Double-Blind, Randomized Placebo-Controlled Study
    Lunzer, R.
    JOURNAL FUR MINERALSTOFFWECHSEL & MUSKULOSKELETTALE ERKRANKUNGEN, 2016, 23 (02): : 60 - 60
  • [37] Efficacy and Safety of Baricitinib in Japanese Patients with Active Rheumatoid Arthritis Receiving Background Methotrexate Therapy: A 12-week, Double-blind, Randomized Placebo-controlled Study
    Tanaka, Yoshiya
    Emoto, Kahaku
    Cai, Zhihong
    Aoki, Takehiro
    Schlichting, Douglas
    Rooney, Terence
    Macias, William
    JOURNAL OF RHEUMATOLOGY, 2016, 43 (03) : 504 - 511
  • [38] EFFICACY AND SAFETY OF BARICITINIB AND TOFACITINIB IN RHEUMATOID ARTHRITIS: DATA FROM REAL-WORLD
    Gonzalez Mazario, R.
    Fragio-Gil, J. J.
    Grau Garcia, E.
    De la Rubia Navarro, M.
    Pavez Perales, C.
    Leal Rodriguez, S.
    Ivorra Cortes, J.
    Negueroles Albuixech, R.
    Gonzalez Puig, L.
    Oller Rodriguez, J. E.
    Alcaniz Escandell, C.
    Vicens Bernabeu, E.
    Chalmeta Verdejo, I.
    Martinez Cordellat, I.
    Ortiz Sanjuan, F. M.
    Najera Herranz, C.
    Canovas Olmos, I.
    Canada Martinez, A. J.
    Roman Ivorra, J. A.
    ANNALS OF THE RHEUMATIC DISEASES, 2020, 79 : 639 - 640
  • [39] Efficacy and safety of baricitinib in rheumatoid arthritis patients with moderate renal impairment: a multicenter propensity score matching study
    Maeyama, Akira
    Kondo, Masakazu
    Harada, Hiroshi
    Shono, Eisuke
    Nagamine, Ryuji
    Tsuru, Tomomi
    Inoue, Yasushi
    Nakashima, Munetoshi
    Yamasaki, Yutaro
    Niiro, Hiroaki
    Nakashima, Yasuharu
    Yamamoto, Takuaki
    BMC RHEUMATOLOGY, 2024, 8 (01)
  • [40] Cardiovascular Safety during Treatment with Baricitinib in Rheumatoid Arthritis
    Weinblatt, Michael
    Taylor, Peter C.
    Burmester, Gerd R.
    Witt, Sarah
    Saifan, Chadi
    Walls, Chad
    Rooney, Terence P.
    Chen, Lei
    Takeuchi, Tsutomu
    ARTHRITIS & RHEUMATOLOGY, 2017, 69
12345